

procedures, specifications, special notations, and precautions to be followed.

§ 211.188 Batch production and control records.

Batch production and control records shall be prepared for each batch of drug product produced and shall include complete information relating to the production and control of each batch. These records shall include:

- (a) An accurate reproduction of the appropriate master production or control record, checked for accuracy, dated, and signed;
- (b) Documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished, including:
 - (1) Dates;
 - (2) Identity of individual major equipment and lines used;
 - (3) Specific identification of each batch of component or in-process material used;
 - (4) Weights and measures of components used in the course of processing;
 - (5) In-process and laboratory control results;
 - (6) Inspection of the packaging and labeling area before and after use;
 - (7) A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing;
 - (8) Complete labeling control records, including specimens or copies of all labeling used;
 - (9) Description of drug product containers and closures;
 - (10) Any sampling performed;
 - (11) Identification of the persons performing and directly supervising or checking each significant step in the operation, or if a significant step in the operation is performed by automated equipment under § 211.68, the identification of the person checking the significant step performed by the automated equipment.
 - (12) Any investigation made according to § 211.192.
 - (13) Results of examinations made in accordance with § 211.134.

[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51933, Sept. 8, 2008]

§ 211.192 Production record review.

All drug product production and control records, including those for packaging and labeling, shall be reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed. Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records) or the failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated, whether or not the batch has already been distributed. The investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy. A written record of the investigation shall be made and shall include the conclusions and followup.

§ 211.194 Laboratory records.

- (a) Laboratory records shall include complete data derived from all tests necessary to assure compliance with established specifications and standards, including examinations and assays, as follows:
 - (1) A description of the sample received for testing with identification of source (that is, location from where sample was obtained), quantity, lot number or other distinctive code, date sample was taken, and date sample was received for testing.
 - (2) A statement of each method used in the testing of the sample. The statement shall indicate the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested. (If the method employed is in the current revision of the United States Pharmacopeia, National Formulary, AOAC INTERNATIONAL, Book of Methods,¹ or in other recognized standard references, or is detailed in an approved new drug application and the

¹Copies may be obtained from: AOAC INTERNATIONAL, 481 North Frederick Ave., suite 500, Gaithersburg, MD 20877.